FIELD: medicine.
SUBSTANCE: invention refers to medicine, more specifically to experimental oncology, pharmacology, namely to a method for assessing the effectiveness of chemoprophylactic activity of resveratrol in experimental carcinogenesis of liver cancer in animals. Method involves administering a substance, personalizing a mathematical model, calculating a probability of developing liver cancer. Resveratrol in dose of 100 mg/kg of body weight is administered into animals together with fodder for 6 months, and biochemical blood values are determined by N-nitrosodiethylamine in dose of 100 mg/l of water for 4 months and 6 months after the beginning of the experiment (MDA, SOD, ALT, AST, Osmotic resistance of erythrocyte membranes, GP, CAT, AP, K+-Na+-ATPases), obtained data are added to the formula: CDLC=-123.353+(1.58×A)-(0.15×B)-(0.55×C)-(3.11×D)-(4.32×E)-(0.88×F)+(13.66×G)+(0.97×H)-(3.96×I)-(54.85×J), where: CDLC – probability of developing liver cancer (%), A – Osmotic resistance of erythrocyte membranes (in% haemolysis), B – MDA (in Mmol/l), C – SOD (in %), D – ALT (in IU/l), E – AST (in IU/l), F – GP (in mcmol/l), G – CAT (in IU/gHb), H – AP (in nmol/s*l), I – K+-Na+-ATPases (in mcmol pH/ml protein/p), J is introduction of resveratrol: 1 – if administered, 0 – if not administered. Obtained result is used to assess the development of liver cancer with subsequent evaluation of the effectiveness of chemoprophylactic activity of resveratrol: 0 to 30 % – high chemoprophylactic activity; from 30 % to 60 % – average chemoprophylactic activity; 60–100 % low chemoprophylactic activity.
EFFECT: disclosed method enables assessing the effectiveness of chemoprophylactic activity of resveratrol in experimental carcinogenesis of liver cancer and calculating an individual clinical prediction, having high accuracy.
1 cl, 1 tbl, 6 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR PREDICTION OF LIVER CANCER RISK IN EXPERIMENTAL ANIMALS | 2018 |
|
RU2699932C1 |
METHOD OF ASSESSING THE SEVERITY OF LIVER DYSFUNCTION IN CATTLE | 2022 |
|
RU2803003C1 |
METHOD FOR ASSESSING THE FUNCTIONAL STATE OF THE LIVER OF CATTLE | 2021 |
|
RU2773414C1 |
CORRECTIVE COMPOSITION FOR PATHOLOGIC CARBOHYDRATE, LIPID DISBOLISM AND ANTIOXIDANT ORGANISM STATE INVOLVEMENT | 2008 |
|
RU2360683C1 |
METHOD OF INCREASING ERYTHROCYTE MEMBRANE STABILITY IN CONDITIONS OF EXPERIMENTAL CARCINOGENESIS | 2015 |
|
RU2588317C1 |
THERAPEUTIC AGENT FOR PREVENTING AND TREATING CHRONIC LIVER DISEASES | 2012 |
|
RU2526172C2 |
METHOD FOR TREATING PATIENTS SUFFERING FROM ACUTE VIRAL HEPATITIS B AGGRAVATED WITH CHOLESTATIC SYNDROME | 2000 |
|
RU2173179C1 |
METHOD OF TREATING MODERATELY ACTIVE AND REPLICATIVE CHRONIC VIRAL HEPATITIS TYPE C OF 1-GENOTYPE | 2009 |
|
RU2398582C1 |
METHOD OF DETERMINING EFFECTIVENESS OF TREATMENT OF ENDOTHELIAL DYSFUNCTION IN METABOLIC AND FUNCTIONAL DISORDERS IN EXPERIMENTAL RATS | 2023 |
|
RU2808420C1 |
METHOD FOR SELECTION OF MEDICINAL PREPARATIONS FOR TREATMENT OF PATIENTS WITH CHRONIC VIRAL HEPATITIS C | 2002 |
|
RU2221243C1 |
Authors
Dates
2020-11-12—Published
2020-05-12—Filed